Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.41 |
| ▸ | KDM5C | P41229 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.36 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28775571 | 0.96 | EGLN1 (0.39) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| Cadaverine Tartrate SCHEMBL8321372 | 0.94 | TSHR (0.42) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| SCHEMBL27314245 | 0.94 | TSHR (0.42) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| SCHEMBL28182002 | 0.92 | TSHR (0.40) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| Cadaverine Tartrate SCHEMBL28179966 | 0.90 | TSHR (0.39) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| SCHEMBL27314244 | 0.90 | EGLN1 (0.35) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| Potassium Ion SCHEMBL28162285 | 0.88 | EGLN1 (0.34) | LMNAEGLN1ALKBH5SUCNR1KDM2A | |
| SCHEMBL94759 | 0.86 | TSHR (0.48) | KDM2ATET2KDM4AKDM4CTET3 | |
| SCHEMBL28205187 | 0.85 | LMNA (0.46) | LMNAALDH1A1TSHRSLC22A6FOLH1 | |
| SCHEMBL7035397 | 0.84 | TSHR (0.46) | KDM2ATET2KDM4AKDM4CTET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007581-A1 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF OCULAR AND OTHER DISEASES | RFE PHARMA LLC (US) | 2017-01-12 | — | — | US | claimed |
| US-20110274748-A1 | CAI-Based Systems and Methods for the Localized Treatment of Ocular and Other Diseases | FORWARDVUE PHARMA, INC. | 2011-11-10 | — | — | US | claimed |
| EP-1802373-B1 | CARBOXY-AMIDO-TRIAZOLES FOR THE LOCALIZED TEATMENT OF OCULAR DISEASES | RFE PHARMA LLC (US) | 2011-07-06 | — | — | EP | claimed |
| CN-1830679-B | Recording paper and method for recording image using the same | FUJI XEROX CORP | 2010-06-23 | — | — | CN | claimed |
| EP-1802373-A2 | CARBOXY-AMIDO-TRIAZOLES FOR THE LOCALIZED TEATMENT OF OCULAR DISEASES | RFE Pharma LLC (US) | 2007-07-04 | — | — | EP | claimed |
| CN-1830679-A | Recording paper and method for recording image using the same | FUJI XEROX CO LTD (JP) | 2006-09-13 | — | — | CN | claimed |
| US-20060116404-A1 | CAI-based systems and methods for the localized treatment of ocular and other diseases | RFE PHARMA LLC | 2006-06-01 | — | — | US | claimed |
| WO-2006037106-A2 | CARBOXY-AMIDO-TRIAZOLES FOR THE LOCALIZED TREATMENT OF OCULAR DISEASES | RFE PHARMA LLC (US) | 2006-04-06 | — | — | WO | claimed |
| EP-3829567-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | With Great Power, LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020023800-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | WITH GREAT POWER, LLC (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20170319550-A1 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS | GEN PHARMA HOLDINGS, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-9669118-B2 | Method of labelling a biologically active molecule with 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9629826-B2 | CAI-based systems and methods for the localized treatment of uveitis | GEN PHARMA HOLDINGS, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170007581-A1 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF OCULAR AND OTHER DISEASES | RFE PHARMA LLC (US) | 2017-01-12 | — | — | US | disclosed |
| EP-0395664-A1 | RENIN INHIBITORS CONTAINING A (1-AMINO-2-HYDROXY-2-HETEROCYCLIC) ETHYL MOIETY | THE UPJOHN COMPANY (US) | 1990-11-07 | — | — | EP | disclosed |
| CN-1008634-B | Contain the lotion-aid combination and the application thereof of ether carboxylate and polycarboxylate and/or ethoxylated amine | PROCTER & GAMBLE (US) | 1990-07-04 | — | — | CN | disclosed |
| US-4897417-A | ANTIGLAUCOMA AGENTS | E. I. DU PONT DE NEMOURS & CO. (US) | 1990-01-30 | — | — | US | disclosed |
| WO-1989003842-A1 | RENIN INHIBITORS CONTAINING A (1-AMINO-2-HYDROXY-2-HETEROCYCLIC) ETHYL MOIETY | THE UPJOHN COMPANY (US) | 1989-05-05 | — | — | WO | disclosed |
| CN-87101761-A | Detergent builder compound containing ether carboxylate and polycarbexylate | — | 1987-09-16 | — | — | CN | disclosed |
| US-4110338-A | Product and preparation of 1H-tetrazole-5-thiol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116404-A1 | CAI-based systems and methods for the localized treatment of ocular and other diseases | CA5B, CA4, CA5A | LMNA 2493/4885EGLN1 822/4885ALKBH5 2704/4885 |
| US-20170319550-A1 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS | PAICS, UACA, CRH | LMNA 3564/4885EGLN1 2942/4885ALKBH5 1654/4885 |
| US-20110274748-A1 | CAI-Based Systems and Methods for the Localized Treatment of Ocular and Other Diseases | CA5B, CA4, CA5A | LMNA 2501/4885EGLN1 811/4885ALKBH5 2714/4885 |
| US-20170007581-A1 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF OCULAR AND OTHER DISEASES | CA5B, CA4, CA5A | LMNA 2493/4885EGLN1 822/4885ALKBH5 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.